INCY

Incyte

Halal Rating :
Comfortable
Last Price $70.90 Last updated:
Market Cap $12.69b
7D Change -2.03%
1 Year Change 15.28%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Services
  • Business Services
  • Services – Research
  • Development
  • Testing Labs
Exchange NASDAQ
Next Earnings Date Oct. 29, 2024

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company's primary focus is on oncology, inflammation, and autoimmunity. Their main products include Jakafi (ruxolitinib), used for treating various types of blood cancers and graft-versus-host disease, and Opzelura (ruxolitinib) cream for treating atopic dermatitis and vitiligo.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $1.14b $992.56m - $774000.0 0.00% 0.08%
June 30, 2024 $1.04b $1.52b - $657000.0 0.00% 0.04%
March 31, 2024 $880.89m $789.42m - $430000.0 0.00% 0.05%

Company Impact

Help us evaluate Incyte's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates